长链非编码RNA MALAT1在肝细胞癌发生发展中的作用

孙永康; 颜学波; 朱泽民; 申鼎成; 谢智钦; 赵志坚; 唐才喜

doi:10.3969/j.issn.1001-5256.2021.03.041

长链非编码RNA MALAT1在肝细胞癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2021.03.041

中南大学湘雅医学院附属株洲医院肝胆胰脾外科，湖南株洲 412007

基金项目:

湖南省自然科学基金项目 (2020JJ5998);

湖南省科技计划项目经费 (2016SK4006)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：孙永康、颜学波负责文献收集，撰写论文；朱泽民、申鼎成、谢智钦参与修改论文；赵志坚、唐才喜负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
孙永康(1993—)，男，从事肝胆胰疾病临床与基础研究

通信作者:
唐才喜，tcx0826@163.com

中图分类号: R735.7
计量
- 文章访问数: 460
- HTML全文浏览量: 187
- PDF下载量: 45
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-08
- 录用日期: 2020-10-20
- 出版日期: 2021-03-20

Role of long non-coding RNA MALAT1 in the development and progression of hepatocellular carcinoma

Department of Hepatobiliary and Pancreatosplenic Surgery, Affiliated Zhuzhou Hospital, Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China

摘要

摘要: 肝细胞癌(HCC)具有发病率高、生存率低、治疗效果不良、发病机制复杂等特点。近年来，多项研究证实lncRNA MALAT1在HCC中表达上调，具有促进HCC细胞增殖、侵袭和转移的作用，并且在HCC的诊断、预后及治疗方面具有临床指导意义。总结了lncRNA MALAT1在HCC中的研究现状，探讨其表达模式、作用机制以及在预测和监测HCC发展中的临床意义，以期深入了解lncRNA MALAT1在介导HCC发展中的作用。lncRNA MALAT1将有望成为HCC诊断和预后的潜在生物标志物，并在将来应用于临床靶点治疗。
- 癌, 肝细胞 /
- RNA, 长链非编码 /
- 肺腺癌转移相关转录子1
Abstract: Hepatocellular carcinoma (HCC) has the features of high incidence rate, low survival rate, poor treatment outcome, and complex pathogenesis. In recent years, many studies have shown that long non-coding RNA (lncRNA) MALAT1 is upregulated in HCC and can promote the proliferation, invasion, and metastasis of HCC cells, and it can also guide the diagnosis, prognostic evaluation, and treatment of HCC in clinical practice. This article reviews the current status of research on lncRNA MALAT1 in HCC and discusses its expression pattern, mechanism of action, and clinical significance in predicting and monitoring the progression of HCC, so as to gain a deep understanding of the role of lncRNA MALAT1 in the progression of HCC. It is pointed out that lncRNA MALAT1 is expected to become a potential biomarker for the diagnosis and prognostic evaluation of HCC and may be used as a therapeutic target in clinical practice.
- Carcinoma, Hepatocellular /
- RNA, Long Noncoding /
- Metastasis-Associated Lung Adenocarcinoma Transcript 1

HTML全文

参考文献(39)

[1]	ZHAO ZB, CHEN F, BAI XF. Long noncoding RNA MALAT1 regulates hepatocellular carcinoma growth under hypoxia via sponging microRNA-200a[J]. Yonsei Med J, 2019, 60(8): 727-734. DOI: 10.3349/ymj.2019.60.8.727
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338
[3]	CHEN S, WANG G, TAO K, et al. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis[J]. Cancer Sci, 2020, 111(5): 1582-1595. DOI: 10.1111/cas.14372
[4]	HE B, PENG F, LI W, et al. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling[J]. J Cell Biochem, 2019, 120(3): 2908-2918. DOI: 10.1002/jcb.26823
[5]	HAN SK, LI ZM, HAN B, et al. Expression of long non-coding RNA MALAT1 in hepatocellular carcinoma tissue and its actions on proliferation and invasion/metastasis of hepatocellular carcinoma cells[J]. Chin J Gen Surg, 2018, 27(1): 49-54. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201801012.htm 韩树坤, 李忠民, 韩冰, 等. 长链非编码RNA MALAT1在肝癌组织中的表达及其在肝癌细胞增殖与侵袭转移中的作用[J]. 中国普通外科杂志, 2018, 27(1): 49-54. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201801012.htm
[6]	PENG N, HE J, LI J, et al. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis[J]. Cancer Cell Int, 2020, 20: 165. DOI: 10.1186/s12935-020-01231-w
[7]	MALAKAR P, STEIN I, SARAGOVI A, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2[J]. Cancer Res, 2019, 79(10): 2480-2493. DOI: 10.1158/0008-5472.CAN-18-1432
[8]	LI ZX, ZHU QN, ZHANG HB, et al. MALAT1: A potential biomarker in cancer[J]. Cancer Manag Res, 2018, 10: 6757-6768. DOI: 10.2147/CMAR.S169406
[9]	YU Q, XIANG L, CHEN Z, et al. MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma[J]. Cell Biosci, 2019, 9: 39. DOI: 10.1186/s13578-019-0299-6
[10]	YUAN LT, CHANG JH, LEE HL, et al. Genetic variants of lncRNA MALAT1 exert diverse impacts on the risk and clinicopathologic characteristics of patients with hepatocellular carcinoma[J]. J Clin Med, 2019, 8(9): 1406. DOI: 10.3390/jcm8091406
[11]	ZHANG X, HAMBLIN MH, YIN KJ. The long noncoding RNA Malat1: Its physiological and pathophysiological functions[J]. RNA Biol, 2017, 14(12): 1705-1714. DOI: 10.1080/15476286.2017.1358347
[12]	LAI MC, YANG Z, ZHOU L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Med Oncol, 2012, 29(3): 1810-1816. DOI: 10.1007/s12032-011-0004-z
[13]	YAO K, ZHANG GJ, HUANG ZM, et al. Long non-coding RNA MALAT1 expression in hepatocellular carcinoma and its action[J]. Chin J Gen Surg, 2016, 25(1): 90-96. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201601020.htm 姚凯, 张光军, 黄忠明, 等. 长链非编码RNA MALAT1在肝癌中表达及功能研究[J]. 中国普通外科杂志, 2016, 25(1): 90-96. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201601020.htm
[14]	HUANG Z, HUANG L, SHEN S, et al. Sp1 cooperates with Sp3 to upregulate MALAT1 expression in human hepatocellular carcinoma[J]. Oncol Rep, 2015, 34(5): 2403-2412. DOI: 10.3892/or.2015.4259
[15]	WANG J, WANG H, ZHANG Y, et al. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer[J]. Cell Signal, 2014, 26(5): 1048-1059. DOI: 10.1016/j.cellsig.2014.01.022
[16]	LI C, CHANG L, CHEN Z, et al. The role of lncRNA MALAT1 in the regulation of hepatocyte proliferation during liver regeneration[J]. Int J Mol Med, 2017, 39(2): 347-356. DOI: 10.3892/ijmm.2017.2854
[17]	FAN L, HUANG X, CHEN J, et al. Long noncoding RNA MALAT1 contributes to sorafenib resistance by targeting miR-140-5p/Aurora-A signaling in hepatocellular carcinoma[J]. Mol Cancer Ther, 2020, 19(5): 1197-1209. DOI: 10.1158/1535-7163.MCT-19-0203
[18]	MALAKAR P, SHILO A, MOGILEVSKY A, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation[J]. Cancer Res, 2017, 77(5): 1155-1167. DOI: 10.1158/0008-5472.CAN-16-1508
[19]	LIU D, ZHU Y, PANG J, et al. Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195[J]. J Cell Biochem, 2018, 119(2): 1368-1380. DOI: 10.1002/jcb.26297
[20]	CHEN L, YAO H, WANG K, et al. Long non-coding RNA MALAT1 regulates ZEB1 expression by sponging miR-143-3p and promotes hepatocellular carcinoma progression[J]. J Cell Biochem, 2017, 118(12): 4836-4843. DOI: 10.1002/jcb.26158
[21]	HOU Z, XU X, FU X, et al. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma[J]. Am J Cancer Res, 2017, 7(4): 845-856.
[22]	LI Y, ZHANG X, ZHENG Q, et al. YAP1 inhibition in HUVECs is associated with released exosomes and increased hepatocarcinoma invasion and metastasis[J]. Mol Ther Nucleic Acids, 2020, 21: 86-97. DOI: 10.1016/j.omtn.2020.05.021
[23]	LIU S, QIU J, HE G, et al. LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression[J]. J Cancer, 2019, 10(26): 6649-6659. DOI: 10.7150/jca.29213
[24]	CUI RJ, FAN JL, LIN YC, et al. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma[J]. Cancer Med, 2019, 8(14): 6358-6369. DOI: 10.1002/cam4.2482
[25]	PAN Y, TONG S, CUI R, et al. Long non-coding MALAT1 functions as a competing endogenous RNA to regulate vimentin expression by sponging miR-30a-5p in hepatocellular carcinoma[J]. Cell Physiol Biochem, 2018, 50(1): 108-120. DOI: 10.1159/000493962
[26]	LI C, MIAO R, LIU S, et al. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis[J]. Oncotarget, 2017, 8(17): 28683-28695. DOI: 10.18632/oncotarget.15640
[27]	HOU Z, XU X, ZHOU L, et al. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1[J]. Tumour Biol, 2017, 39(7): 1010428317718135.
[28]	HOU ZH, XU XW, FU XY, et al. Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140[J]. Am J Physiol Cell Physiol, 2020, 318(3): c649-c663. DOI: 10.1152/ajpcell.00510.2018
[29]	ZHANG P, HA M, LI L, et al. MicroRNA-3064-5p sponged by MALAT1 suppresses angiogenesis in human hepatocellular carcinoma by targeting the FOXA1/CD24/Src pathway[J]. FASEB J, 2020, 34(1): 66-81. DOI: 10.1096/fj.201901834R
[30]	DUAN YF, ZHAO QX, JING X. Effect of long non-coding RNAs on glycolytic pathway in primary liver cancer and related mechanisms[J]. J Clin Hepatol, 2019, 35(6): 1374-1376. DOI: 10.3969/j.issn.1001-5256.2019.06.043 段艺菲, 赵清喜, 荆雪. 长链非编码RNA对原发性肝癌中糖酵解途径的影响机制[J]. 临床肝胆病杂志, 2019, 35(6): 1374-1376. DOI: 10.3969/j.issn.1001-5256.2019.06.043
[31]	HUANG M, WANG H, HU X, et al. lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression[J]. Oncoimmunology, 2019, 8(1): e1518628. DOI: 10.1080/2162402X.2018.1518628
[32]	CHEN L, KONG R, WU C, et al. Circ-MALAT1 functions as both an mRNA translation brake and a microRNA sponge to promote self-renewal of hepatocellular cancer stem cells[J]. Adv Sci (Weinh), 2019, 7(4): 1900949.
[33]	WANG C, ZHANG Q, HU Y, et al. Emerging role of long non-coding RNA MALAT1 in predicting clinical outcomes of patients with digestive system malignancies: A meta-analysis[J]. Oncol Lett, 2019, 17(2): 2159-2170. http://www.onacademic.com/detail/journal_1000041698573399_a18c.html
[34]	TORAIH EA, ELLAWINDY A, FALA SY, et al. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma[J]. Biomed Pharmacother, 2018, 102: 653-669. DOI: 10.1016/j.biopha.2018.03.105
[35]	LIU F, LI T, ZHANG L, et al. PAMAM/polyhedral nanogold-modified probes with DNAase catalysis for the amperometric electrochemical detection of metastasis-associated lung adenocarcinoma transcript?[J]. J Biol Eng, 2019, 13: 21. DOI: 10.1186/s13036-019-0149-4
[36]	LIU XQ, WANG X, LIU C, et al. Expression and clinical significance of long chain non-coding MALAT1 RNA in patients with hepatocellular carcinoma[J]. Tianjin Med J, 2016, 44(12): 1484-1488. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201612020.htm 刘兴强, 王霞, 刘超, 等. 长链非编码RNA MALAT1在肝细胞癌行肝切除患者中的表达及临床意义[J]. 天津医药, 2016, 44(12): 1484-1488. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201612020.htm
[37]	JI DG, GUAN LY, LUO X, et al. Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway[J]. Biochem Biophys Res Commun, 2018, 501(1): 33-40. DOI: 10.1016/j.bbrc.2018.04.116
[38]	YUAN P, CAO W, ZANG Q, et al. The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy[J]. Biochem Biophys Res Commun, 2016, 478(3): 1067-1073. DOI: 10.1016/j.bbrc.2016.08.065
[39]	CHANG HL, BAMODU OA, ONG JR, et al. Targeting the epigenetic non-coding RNA MALAT1/Wnt signaling axis as a therapeutic approach to suppress stemness and metastasis in hepatocellular carcinoma[J]. Cells, 2020, 9(4): 1020. DOI: 10.3390/cells9041020